PCM
AQST icon

Pavaki Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Pavaki Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$520K Hold
125,000
– – 0.18% 87
2026
Q1 		$519K Hold
125,000
– – 0.22% 76
2025
Q4 		$808K Buy
+125,000
New +$779K 0.32% 51

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Pavaki Capital Management's AQST Position: Q2 2026 in Review

Pavaki Capital Management held its Aquestive Therapeutics (AQST) position steady in Q2 2026 at 125,000 shares worth $520K. The position accounts for 0.18% of the portfolio, ranked #87.

Pavaki Capital Management first reported a position in AQST in Q4 2025 and has held it in 3 quarters since. The position peaked at $808K in Q4 2025. 173 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Pavaki Capital Management held 125,000 shares of Aquestive Therapeutics worth $520K as of Q2 2026.
  • Pavaki Capital Management left its Aquestive Therapeutics share count unchanged in Q2 2026.
  • Aquestive Therapeutics made up 0.18% of Pavaki Capital Management's portfolio in Q2 2026, its #87 holding.
  • Pavaki Capital Management first reported a position in Aquestive Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Pavaki Capital Management's Aquestive Therapeutics position peaked at $808K in Q4 2025.
  • 173 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Pavaki Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.